High-Dose Chemotherapy with Bone-Marrow Rescue for Breast Cancer — the Proof Was Faked

Between roughly 1989 and 2002 American oncologists put an estimated 30,000–40,000 women with breast cancer through high-dose chemotherapy with autologous bone-marrow or stem-cell rescue (HDC/ABMT) before a single randomized trial had shown it saved lives; when the trials reported in 2000, the gap between promise and result was total. The regimen — massive cytotoxic doses that destroyed the marrow, followed by reinfusion of the patient’s banked cells to keep her alive — offered no survival benefit over conventional-dose chemotherapy, killed a meaningful fraction of patients through treatment-related toxicity, and cost an estimated $3.4 billion to deliver. The one study claiming a dramatic advantage was found to be fraudulent.

The procedure was never FDA-approved as a breast-cancer cure and never validated by a controlled trial during its boom. It spread on a seductive mechanistic story — breast cancer was dose-responsive, so more poison meant more cures — and on a litigation campaign that turned insurers’ refusal to pay into public scandal. The 1993 Fox v. Health Net verdict, awarding a dead schoolteacher’s family $89 million including $77 million in punitive damages, taught every HMO that denying the transplant was costlier than paying for it; coverage cascaded and four state legislatures mandated it.

The keystone of clinical belief was the work of South African oncologist Werner Bezwoda of the University of the Witwatersrand, whose trials alone reported a roughly three-fold survival advantage; when four randomized trials were presented together at the 1999 American Society of Clinical Oncology (ASCO) meeting, the other three showed no benefit. U.S. auditors who reached Johannesburg in early 2000 found his randomization existed only on paper and his control group had never received the standard treatment he reported. He was fired for “scientific misrepresentation” in 2000 and the Journal of Clinical Oncology retracted his work in 2001. HDC/ABMT for breast cancer is now the textbook case of an unproven, lethal intervention scaled to tens of thousands by hope, courtroom pressure, and a single fraud — abandoned not because it was banned, but because the evidence it had skipped finally arrived and demolished it.